The two companies will utilize the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform, which includes the company’s point of care (POCare) network and associated technologies. Orgenesis’ POC Network includes leading hospitals and research institutes around the world, the company said.
The first collaboration will focus on the development of CAR-T and whole-cell-based vaccine platform for use in cancer immunotherapies. The parties also plan to collaborate with local medical centers.
“This latest collaboration with Educell expands our activities in Europe and we believe that it should help us launch our therapies into additional European hospitals, as well as help Educell commercialize their therapies around the world,” Orgenesis CEO Vered Caplan said in a statement.
“We also believe that this collaboration reinforces the significant value proposition and flexibility of our CGT Biotech Platform,” Caplain added. “We look forward to benefiting from the expertise of Educell as we seek to expand our automated T-cell culturing approach into clinical validation and commercialization phases.”
Educell is currently preparing cell therapy products for the treatment of articular cartilage, vesicoureteral reflux, regeneration of bone tissue and treatment of immunological disorders, which are in use at the University Medical Centre Ljubljana and other institutions in Slovenia.
“We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies,” Educell CEO Miomir Knežević said. “This collaboration reflects our commitment to bringing new, effective and affordable cell and gene therapy products to cancer patients worldwide while highlighting Educell’s ability to ensure safety in the process and help to reduce overall manufacturing costs.”
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel